TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24685997

Group type: EXPERIMENTAL
Intervention: Parents as Teachers Enhanced (experimental arm)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Parents as Teachers (control arm)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 150
Study: 21760491

Group type: EXPERIMENTAL
Intervention: Psychoeducational support program (individual education, telephone health-coaching, small-group meetings)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Psychoeducational support program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no psychoeducational support)
Number of subjects: 48
Study: 20156156

Group type: EXPERIMENTAL
Intervention: Second- and third-line antituberculosis agents
Number of subjects: 0
Study: 18715216

Group type: EXPERIMENTAL
Intervention: Pramlintide (30/60 microg administered subcutaneously at each meal)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 16180526

Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term psychotherapy (PSTP), 25 therapy sessions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term psychotherapy (PSTP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Child Behavior Checklist (CBCL)
Number of subjects: 26
Study: 12558711

Group type: EXPERIMENTAL
Intervention: Low‐intensity, functionally oriented exercise and incontinence care provided every 2 hours from 8:00 a.m. to 4:00 p.m. for 5 days a week for 8 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Low‐intensity, functionally oriented exercise and incontinence care
Number of subjects: 190
Study: 10867984

Group type: EXPERIMENTAL
Intervention: mecamylamine (20 mg PO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: mecamylamine (20 mg PO) and donepezil (5 mg PO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 8661208

Group type: EXPERIMENTAL
Intervention: Enteral liquid diet containing arginine and glutamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with pharmacologic amounts of glutamine and arginine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Standard enteral liquid diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 14
Study: 1829029

Group type: EXPERIMENTAL
Intervention: EE-DG (Ethinylestradiol 30 micrograms + Desogestrel 150 micrograms)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EE-GD (Ethinylestradiol 30 micrograms + Gestodene 75 micrograms)
Number of subjects: 40
Study: 6866592

Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl (Ritalin) administered intravenously or orally with breakfast
Number of subjects: 7

Group type: COMPARATOR
Intervention: Methylphenidate HCl (Ritalin) administered intravenously or orally in a fasted state
Number of subjects: 7
Study: 31965899

Group type: EXPERIMENTAL
Intervention: High viscosity cement (group A, n = 27 patients) with 2.8 mm cannula
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low viscosity cement (group B, n = 25 patients) with 4.2 mm cannula
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High viscosity cement (group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low viscosity cement (group B)
Number of subjects: 52
Study: 30649213

Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate (HLC) diet
Number of subjects: 609

Group type: COMPARATOR
Intervention: Healthy low-fat (HLF) diet
Number of subjects: 609
Study: 29121989

Group type: EXPERIMENTAL
Intervention: PT-led primary care model for back pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual physician‐led primary care model
Number of subjects: 0
Study: 25963022

Group type: EXPERIMENTAL
Intervention: Supplemental vitamins K and D and calcium
Number of subjects: 0
Study: 22749707

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:100,000
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:200,000
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 42
Study: 22420108

Group type: EXPERIMENTAL
Intervention: Self-rating of personality traits
Number of subjects: 154

Group type: COMPARATOR
Intervention: Average peer rating of personality traits
Number of subjects: 154
Study: 19566950

Group type: EXPERIMENTAL
Intervention: Patient education program including in-office physician counseling and patient mailings
Number of subjects: 0
Study: 17718018

Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodized salt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated household conditions
Number of subjects: 0
Study: 15849207

Group type: EXPERIMENTAL
Intervention: Pethidine 20 mg (Group P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1) (Group K)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (Group S)
Number of subjects: 90
Study: 12221161

Group type: EXPERIMENTAL
Intervention: STN stimulation with voltages >= 3 V and frequencies >= 130 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: STN stimulation with a rate of 5 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of highest voltage with narrowest pulse width
Number of subjects: 12
Study: 10458252

Group type: EXPERIMENTAL
Intervention: CJ‐11,974 100 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7798528

Group type: EXPERIMENTAL
Intervention: Etilefrine (10 mg three times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2086821

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) alone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) plus Cefmetazole (CMZ)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) plus Piperacillin (PIPC)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) plus Amikacin (AMK)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall efficacy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Infections caused by Gram-negative bacilli
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination of AZT and CMZ or PIPC for Escherichia coli infections
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Efficacy rates by neutrophil counts
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Infections with unidentified causative organisms
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Infections with identified causative organisms
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sepsis and suspected sepsis
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pneumonia and respiratory tract infection
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fever of undetermined origin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Other infections
Number of subjects: 104
Study: 349582

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study: 31842974

Group type: EXPERIMENTAL
Intervention: Electronic chest drainage system (Drentech™ Palm Evo)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Traditional chest drainage system (Drentech™ Compact)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Digital chest drainage system
Number of subjects: 382
Study: 27808417

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 25884315

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (1.2 g.kg(‐1) body mass.h(‐1) in a 20% CHO solution)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) supplementation (6 mg.kg(‐1) body mass)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined CHO and CAF (CHO+CAF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23665888

Group type: EXPERIMENTAL
Intervention: Acupuncture at the PC6 point
Number of subjects: 228

Group type: COMPARATOR
Intervention: No preventive care (routine medical treatment)
Number of subjects: 228
Study: 21819189

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (coil placement)
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Neurosurgical treatment (clip occlusion)
Number of subjects: 2143
Study: 19135345

Group type: EXPERIMENTAL
Intervention: High-dose parenteral vinpocetine (VP) at doses gradually increased to 1 mg/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral vinpocetine (VP) 30 mg for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study: 17955649

Group type: EXPERIMENTAL
Intervention: Point-penetrating acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Body acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 15472176

Group type: EXPERIMENTAL
Intervention: GH at 25.0 microg/kg x d (pediatric dose)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: GH at 12.5 microg/kg x d (adult dose)
Number of subjects: 149

Group type: COMPARATOR
Intervention: GH treatment (both doses)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (no GH treatment)
Number of subjects: 149
Study: 11549829

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg twice daily), Amoxycillin (1000 mg twice daily), Clarithromycin (500 mg twice daily) for 14 days (LAC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg four times daily), Bismuth subsalicylate (2 tablets four times daily), Metronidazole (250 mg four times daily), Tetracycline (250 mg four times daily) for 14 days (LBMT)
Number of subjects: 48
Study: 9610529

Group type: EXPERIMENTAL
Intervention: High baseline levels of C-reactive protein (CRP)
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Total cholesterol (TC)
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Models incorporating CRP and lipid parameters
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Baseline CRP level
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Analyses limited to nonsmokers and after control for other cardiovascular risk factors
Number of subjects: 14916
Study: 8111257

Group type: EXPERIMENTAL
Intervention: Low total fat diet (8% saturated fat, approximately 200 mg/day cholesterol)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High unsaturated fat diet (8% saturated fat, approximately 200 mg/day cholesterol)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal control diet
Number of subjects: 63
Study: 2972548

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 0
Study: 49649

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 4121

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4121
Study: 30969846

Group type: EXPERIMENTAL
Intervention: Salvage autologous stem-cell transplantation (sASCT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Nontransplantation consolidation (NTC)
Number of subjects: 288
Study: 26181504

Group type: EXPERIMENTAL
Intervention: Viscous lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 100
Study: 26521106

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CYA) combined with low-dose corticosteroids (CS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cyclophosphamide (CPA) combined with low-dose corticosteroids (CS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CYA and CPA groups
Number of subjects: 99
Study: 23599381

Group type: EXPERIMENTAL
Intervention: Sevelamer (n=55)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n=54)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevelamer (compliant subgroup)
Number of subjects: 120
Study: 22080720

Group type: EXPERIMENTAL
Intervention: Small class size (13-17 students)
Number of subjects: 11601
Study: 19420364

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 3006

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 3006
Study: 16807142

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Colistin (C)
Number of subjects: 21
Study: 12651203

Group type: EXPERIMENTAL
Intervention: salvage HD-CT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: complete resection of residual masses
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: favourable response to salvage therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: no specific therapy
Number of subjects: 58
Study: 11147613

Group type: EXPERIMENTAL
Intervention: Semiannual chest X-rays and sputum investigation (intervention group, 3171 participants)
Number of subjects: 6364

Group type: COMPARATOR
Intervention: One examination only by chest X-rays and sputum investigation (control group, 3174 participants)
Number of subjects: 6364
Study: 8935624

Group type: EXPERIMENTAL
Intervention: Infrared video camera system for measuring nocturnal scratching
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (non-itchy healthy controls)
Number of subjects: 10
Study: 1576095

Group type: EXPERIMENTAL
Intervention: Low-dose nisoldipine (2 micrograms/kg) as a single intravenous injection over a 3-minute period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose nisoldipine (double the low dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2579496

Group type: EXPERIMENTAL
Intervention: Minimal transurethral prostatic resection (TUR-P)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Total transurethral prostatic resection (TUR-P)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study: 30935335

Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation (CSM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham CSM
Number of subjects: 28
Study: 29235186

Group type: EXPERIMENTAL
Intervention: WebQuit.org (ACT for smoking cessation)
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Smokefree.gov (US Clinical Practice Guidelines for smoking cessation)
Number of subjects: 2637
Study: 27244700

Group type: EXPERIMENTAL
Intervention: HYADD 4
Number of subjects: 75

Group type: COMPARATOR
Intervention: Corticosteroid (CS)
Number of subjects: 75
Study: 24576886

Group type: EXPERIMENTAL
Intervention: PACK-CXL treatment in addition to antimicrobial therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antimicrobial therapy only (Control group)
Number of subjects: 40
Study: 22556101

Group type: EXPERIMENTAL
Intervention: Installation of bedside alcohol hand rub and materials promoting hand hygiene, with regular hand hygiene audits, rolled out nationally from 1 December 2004.
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Increased procurement of soap
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Increased procurement of alcohol hand rub
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Publication of the Health Act 2006
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Trust visits by Department of Health improvement teams
Number of subjects: 187
Study: 20349405

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.7 g for three months)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 206
Study: 18751997

Group type: EXPERIMENTAL
Intervention: 2DW (n = 25) - participated in 90‐min group training twice a week for 12 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 1DW (n = 29) - participated in 90‐min group training once a week for 12 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: CONTROL (n = 23) - no training
Number of subjects: 77
Study: 11413076

Group type: EXPERIMENTAL
Intervention: Lamifiban (an intravenous GP IIb/IIIa antagonist)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 1160
Study: 9786314

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by prolonged infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New topoisomerase I inhibitor irinotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional treatments (resection of hepatic metastases)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different chemotherapy regimens (including nitrosoureas, mitomycin C, or cisplatin)
Number of subjects: 0
Study: 7841265

Group type: EXPERIMENTAL
Intervention: Telephone prompts (telephone call in anticipation of a mailed questionnaire)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional mailing (mailed questionnaires and reminder letter)
Number of subjects: 100
Study: 3282482

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31209171

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2 hours per week for 5 school years
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group activities (conventional calculation and reading)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: AMC training
Number of subjects: 144
Study: 28653108

Group type: EXPERIMENTAL
Intervention: Antioxidant-containing ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Antioxidant-containing ointment
Number of subjects: 32
Study: 25382593

Group type: EXPERIMENTAL
Intervention: Third-party intentions influencing judgments of blame
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-party intentions influencing moral judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in causal perception due to third-party intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution of blame and perceived differences in situational constraint
Number of subjects: 0
Study: 23460815

Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Antioxidant
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin & antioxidant
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 21569300

Group type: EXPERIMENTAL
Intervention: Problem solving therapy, postcards, patient support, cultural assessment, improved access to primary care, risk management strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 19755656

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 156
Study: 16531621

Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg/kg of body weight) for 6 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo for 6 days
Number of subjects: 78
Study: 14641514

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 25
Study: 10831942

Group type: EXPERIMENTAL
Intervention: Urgent/Emergent Surgery
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Elective Surgery
Number of subjects: 1100

Group type: COMPARATOR
Intervention: No Surgery
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Cardiac Surgery (overall)
Number of subjects: 1100
Study: 9084611

Group type: EXPERIMENTAL
Intervention: Assisting torque of 8‐15 Nm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Opposing torque of 8‐15 Nm
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control trials (no perturbation)
Number of subjects: 6
Study: 8458913

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29633621

Group type: EXPERIMENTAL
Intervention: OMEGA-3 PUFA-enriched eggs (3 eggs daily, 259 mg omega-3 PUFAs/egg for 3 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ordinary hen eggs (3 eggs daily, 277 mg omega-3 PUFAs/day for 3 weeks)
Number of subjects: 36
Study: 28767068

Group type: EXPERIMENTAL
Intervention: Viewing relevant health warnings
Number of subjects: 4072

Group type: COMPARATOR
Intervention: Viewing other warnings
Number of subjects: 4072

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 4072

Group type: COMPARATOR
Intervention: General, text-only warnings (in Korea)
Number of subjects: 4072

Group type: COMPARATOR
Intervention: Detailed pictorial warnings (in Mumbai)
Number of subjects: 4072
Study: 24390764

Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg intravenously twice a day for 14 days)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 23718078

Group type: EXPERIMENTAL
Intervention: Gas-air carbonate baths
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lysozyme inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined application of gas-air carbonate baths and lysozyme inhalation
Number of subjects: 0
Study: 21430703

Group type: EXPERIMENTAL
Intervention: 0.75% LDE225 cream
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study: 18829872

Group type: EXPERIMENTAL
Intervention: Acute and maintenance interpersonal and social rhythm therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute interpersonal and social rhythm therapy and maintenance intensive clinical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute intensive clinical management and maintenance interpersonal and social rhythm therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive clinical management
Number of subjects: 0